• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    11/5/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $LOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held November 4th are now available for online viewing.

    VIEW PRESENTATIONS HERE

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    November 4th Company Presentations

    HUTCHMED (China) Limited(AIM: HCM, NASDAQ:HCM, and HKEX:13)
    First Pacific Company Ltd((HKEX: 142, OTC:FPAFY)
    Viomi Technology Co., Ltd(NASDAQ:VIOT)
    Epiroc AB((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    Yiren Digital Ltd.(NYSE:YRD)
    Belite Bio, Inc (NASDAQ:BLTE)
    Deutsche Lufthansa AG((FRA: LHA, OTCQX:DLAKY)
    Lotus Technology Inc(NASDAQ:LOT)
    51Talk Online Education Group(NYSE:COE)
    Radiopharm Theranostics Ltd(NASDAQ:RADX, ASX: RAD))
    Repsol S.A((BME: REP, OTCQX:REPYY)
      

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $LOT

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Radiopharm Theranostics Limited
    $RADX
    3/12/2025$15.00Buy
    B. Riley Securities
    Belite Bio Inc
    $BLTE
    12/14/2023$60.00Buy
    Maxim Group
    HUTCHMED (China) Limited
    $HCM
    11/24/2023Hold → Buy
    Deutsche Bank
    Belite Bio Inc
    $BLTE
    7/28/2023$43.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    7/26/2023$25.00Outperform
    SVB Securities
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $LOT
    SEC Filings

    View All

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    11/20/25 6:18:37 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    11/19/25 8:00:03 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    11/18/25 6:07:09 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

    RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 clinical trial of its Kallikrein Related Peptidase 3 (KLK3)-targeting radiotherapeutic, RAD 402, for t

    11/18/25 8:30:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yiren Digital to Report Third Quarter 2025 Financial Results on November 25, 2025

    BEIJING, Nov. 18, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025 before U.S. market opens on Tuesday, November 25, 2025. Yiren Digital's management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time on November 25, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on November 25, 2025). Participants who wish to join the call should register online in advance of the conference at: https

    11/18/25 2:30:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

    Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26 SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold. "Enrolling 50% of the patients in our Phase 2b study of RAD101 is a meaningful achievement for

    11/17/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Belite Bio with a new price target

    Mizuho initiated coverage of Belite Bio with a rating of Neutral and set a new price target of $105.00

    11/20/25 8:06:38 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded HUTCHMED from Equal-Weight to Underweight and set a new price target of $13.75

    9/22/25 8:24:03 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED downgraded by HSBC Securities

    HSBC Securities downgraded HUTCHMED from Buy to Hold

    5/13/25 3:20:36 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $LOT
    Financials

    Live finance-specific insights

    View All

    Yiren Digital to Report Third Quarter 2025 Financial Results on November 25, 2025

    BEIJING, Nov. 18, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025 before U.S. market opens on Tuesday, November 25, 2025. Yiren Digital's management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time on November 25, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on November 25, 2025). Participants who wish to join the call should register online in advance of the conference at: https

    11/18/25 2:30:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Lotus Technology to Report Unaudited Third Quarter 2025 Financial Results on November 24, 2025

    NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced that it will report its unaudited financial results for the third quarter 2025 on November 24, 2025, before market opening in the United States. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on Monday, November 24 , 2025 (13:00 Central European Time / 20:00 China Standard Time on the same day). There will be a live audio webcast and limited-time replay available on the Company's investor relations website at https://ir.group-lotus.com/news-events/events/ For part

    11/10/25 7:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    51Talk Online Education Group Announces Second Quarter 2025 Results

    SINGAPORE, Sept. 3, 2025 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial and Operating Highlights Gross billings[1] for the second quarter of 2025 were US$28.5 million, a 79.7% growth from US$15.9 for the second quarter of 2024.Net revenues for the second quarter of 2025 were US$20.4 million, an 86.1% increase from US$11.0 million for the second quarter of 2024.The number of quarterly active students with attended lesson consumption for the second quarter of 2025

    9/3/25 5:00:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    $BLTE
    $COE
    $HCM
    $LOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    $BLTE
    $COE
    $HCM
    $LOT
    Leadership Updates

    Live Leadership Updates

    View All

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care